Can Buspirone Cause Mania?
Yes, buspirone can cause mania or manic-like symptoms, though this is an uncommon adverse effect that occurs in approximately 8-24% of certain patient populations, particularly children with pre-existing psychiatric conditions.
Evidence from FDA Drug Labeling
The FDA-approved prescribing information for buspirone does not list mania as a common adverse effect in the general population 1. However, the drug label notes that buspirone binds to central dopamine receptors and can cause neuropsychiatric changes, including a syndrome of restlessness and agitation appearing shortly after treatment initiation 1. The label emphasizes that buspirone's CNS effects in any individual patient may not be predictable 1.
Clinical Evidence of Mania Induction
Pediatric Populations (Highest Risk)
- In a study of 25 prepubertal psychiatric inpatients treated with buspirone for anxiety and aggression, 2 patients (8%) developed euphoric mania, requiring discontinuation of the medication 2.
- An additional 4 patients (16%) in the same study developed increased aggression and agitation, bringing the total rate of behavioral adverse effects to 24% 2.
- Two case reports documented possible psychotic deterioration in children treated with buspirone for anxiety 3.
Adult Populations
- A 2023 case report documented worsening psychosis in a patient with schizoaffective disorder when buspirone was administered on two separate occasions, with symptoms including increased aggression, paranoia, and odd behaviors 4.
- A 2002 case report described hypomania in a patient taking buspirone combined with fluoxetine and herbal supplements (St. John's wort and Ginkgo biloba), which remitted after discontinuing the herbal medicines 5.
- A large-scale pharmacovigilance study analyzing the FAERS database identified psychiatric disorders as one of the most common categories of adverse events with buspirone, though specific rates of mania were not separately quantified 6.
Mechanism of Action Considerations
The mechanism by which buspirone may induce mania likely relates to its complex dopaminergic effects 4. While buspirone primarily acts as a 5-HT1A receptor partial agonist, it also functions as an antagonist at presynaptic dopamine D2, D3, and D4 receptors 4. Paradoxically, rather than producing antipsychotic effects, this dopamine antagonism can result in substantial increases in dopaminergic metabolites, potentially contributing to manic symptoms 4.
Clinical Implications and Risk Factors
High-Risk Populations
- Children and adolescents with pre-existing psychiatric conditions (anxiety, aggression, mood disorders) appear to be at highest risk 2, 3.
- Patients with psychotic disorders or schizoaffective disorder should receive buspirone with extreme caution, if at all 4.
- Patients with traumatic brain injury may have increased vulnerability to mood destabilization 5.
Drug Interactions
- Combining buspirone with SSRIs (particularly fluoxetine) may increase the risk of mood destabilization and serotonin syndrome 1, 5.
- The FDA label contraindicates use with MAOIs due to risk of serotonin syndrome and elevated blood pressure 1.
- Herbal supplements with serotonergic properties (St. John's wort) may potentiate manic symptoms when combined with buspirone 5.
Monitoring Recommendations
- Close monitoring is essential during the first 3 weeks of treatment, particularly in children and patients with psychiatric comorbidities 2.
- Watch specifically for: euphoric mood, increased energy, decreased need for sleep, increased aggression, agitation, paranoia, and psychotic symptoms 2, 4.
- If manic symptoms emerge, buspirone should be discontinued immediately 2.
- The median time to onset of adverse psychiatric events is 10 days, though this can vary 6.
Important Caveats
Route of administration matters: Intranasal administration (through pill crushing and nasal ingestion) dramatically increases bioavailability from 4% to much higher levels, potentially intensifying adverse psychiatric effects 4. One patient in a case report admitted to hiding pills for later intranasal consumption, which preceded symptom exacerbation 4.
Distinguishing mania from behavioral activation: True mania typically appears later in treatment and persists after drug discontinuation, requiring active pharmacological intervention, whereas behavioral activation occurs early (first month) and resolves quickly after dose reduction or discontinuation 7.